Rituximab-Resistant Nephrotic Syndrome With Successful Induction of Remission by Low-Density Lipoprotein Apheresis

Ther Apher Dial. 2017 Jun;21(3):295-296. doi: 10.1111/1744-9987.12561.

Authors

Hiroyuki Suzuki¹, Tatsuo Tsukamoto¹, Eri Muso¹

Affiliation

¹ Division of Nephrology and Dialysis, Kitano Hospital, The Tazuke Kofukai Medical Research Institute, Osaka, Japan.

PMID: 28661090
DOI: 10.1111/1744-9987.12561

No abstract available

Keywords: low-density lipoprotein apheresis; minimal change nephrotic syndrome; rituximab.

Publication types

Case Reports
Letter

MeSH terms

Blood Component Removal / methods*
Female
Humans
Immunologic Factors / therapeutic use
Lipoproteins, LDL / blood*
Nephrotic Syndrome / physiopathology
Nephrotic Syndrome / therapy*
Remission Induction
Rituximab / therapeutic use*
Treatment Outcome
Young Adult

Substances

Immunologic Factors
Lipoproteins, LDL
Rituximab